Reference
Padula WV, et al. Market Exclusivity for Drugs with Multiple Orphan Approvals (1983-2017) and Associated Budget Impact in the US. PharmacoEconomics : 12 Jun 2020. Available from: URL: https://doi.org/10.1007/s40273-020-00934-2
Rights and permissions
About this article
Cite this article
Multiple orphan drugs have extended exclusivity periods in the US. PharmacoEcon Outcomes News 856, 20 (2020). https://doi.org/10.1007/s40274-020-6920-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-6920-4